A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Semaglutide 7.2 mg is also being assessed in adults with obesity and type 2 diabetes in the STEP UP T2D trial. Top-line results from STEP UP T2D are expected in the next few months, according to ...

“The UCI takes a bold and necessary stance by banning the repeated use of carbon-monoxide inhalation on medical grounds,” UCI ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

However, recent data from several studies (STEP-1, STEP-4, SURMOUNT-4) suggest that following discontinuation of the GLP-1 drugs semaglutide and tirzepatide ... 2b study in our lead indication, AIWG." ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...